Intrathecal baclofen therapy in stiff-man syndrome: A double-blind, placebo-controlled trial

P. L. Silbert, J. Y. Matsumoto, P. G. McManis, K. A. Stolp-Smith, B. A. Elliott, K. M. McEvoy

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

We performed a double-blind, placebo-controlled trial of intrathecal baclofen (ITB) in stiff-man syndrome. Three patients, unresponsive to current therapy, received 50 mu g of ITB or placebo on sequential days. Following ITB, all patients demonstrated improvement in reflex EMG activity. The mean reduction in total EMG activity (from all muscles) following stimulation of the medial plantar nerve (cutaneous flexor reflex) was 72% following 50 mu g of ITB compared with 18% following placebo (ANOVA: significance of F, p less than 0.0001). The mean latency to onset of the response was also significantly prolonged for all muscles following ITB (ANOVA: significance of F, p less than 0.05). Although reflex EMG activity was reduced in all patients, clinical improvement was evident in only one patient, who differed from the others studied by a longer duration of disease, greater severity of stiffness, less fear of falling, and greater electrophysiologic improvement.

Original languageEnglish (US)
Pages (from-to)1893-1897
Number of pages5
JournalNeurology
Volume45
Issue number10
DOIs
StatePublished - Oct 1995

Fingerprint Dive into the research topics of 'Intrathecal baclofen therapy in stiff-man syndrome: A double-blind, placebo-controlled trial'. Together they form a unique fingerprint.

  • Cite this

    Silbert, P. L., Matsumoto, J. Y., McManis, P. G., Stolp-Smith, K. A., Elliott, B. A., & McEvoy, K. M. (1995). Intrathecal baclofen therapy in stiff-man syndrome: A double-blind, placebo-controlled trial. Neurology, 45(10), 1893-1897. https://doi.org/10.1212/WNL.45.10.1893